Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from iX Biopharma Ltd. ( (SG:42C) ).
iX Biopharma Ltd. has announced the issuance and allotment of 2,914,771 new ordinary shares to three directors, increasing the total number of issued shares to 887,959,445. This move, which slightly dilutes existing shares by 0.33%, is expected to enhance the company’s governance structure and align the interests of the directors with those of shareholders, potentially impacting the company’s market positioning positively.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a company incorporated in Singapore, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapies, primarily targeting the pharmaceutical and healthcare markets.
Average Trading Volume: 291,434
Technical Sentiment Consensus Rating: Buy
Current Market Cap: S$20.36M
For an in-depth examination of 42C stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue